Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
News
2015
2014
More work needed on new EMA conflicts of interest policy
Student Stop AIDS National Gathering an inspiring start to Access to Medicines Week
EMA policy on clinical data publication a step ahead, but falls short of true potential
Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry
Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA
Organic farming practices at Highgrove could offer "princely" contribution to curtailing antibiotic resistance
School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis
Setting precedents: EMA must get clinical trial data policy right to truly act in public interest
HAI Europe calls on EMA's Management Board to stand for data transparency
BMJ statins debate about scientific independence, not rigour
Hoping for "harmony" on global antibiotic resistance strategy
Week in review: Outcomes from WHA67
Progress on access to medicines at WHA67, but WHO funding sorely needed
World Health Assembly: HAI and ARC intervention on antimicrobial resistance, including antibiotic resistance
World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development
World Health Assembly 67: HAI intervention on access to essential medicines
World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors
Action on antimicrobial resistance: It’s about time (and we’re running out)
Tamiflu review shows desperate need for full clinical trials data transparency
Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply
New materials help assess medicines policies and interventions
A new (and improved) model to regulate pharmaceutical promotion
Enhancing accountability in the medicines market: The Medicines Transparency Alliance
Bayer CEO's callous comments highlight failure of current biomedical innovation model
Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed
Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed
Regulation critical to clinical trials data transparency in Europe
2013